Does HPV cause endometrial cancer? No — the evidence does not support a causal role. Human papillomavirus (HPV) is a sexually transmitted virus with strong, well-established links to cervical, anal, and oropharyngeal cancers, but endometrial cancer arises through different biology: unopposed estrogen exposure, metabolic and hormonal factors, and specific genetic mutations in the uterine lining. HPV DNA is found in only a small minority of endometrial tumors, and its presence has not been shown to drive them.

The distinction matters because HPV is common and the endometrium is not a typical HPV target. HPV infects basal epithelial cells of squamous and glandular surfaces, particularly the cervical transformation zone. The endometrium is a columnar glandular lining deeper inside the uterus, physically and immunologically separated from the cervix. That anatomy alone makes direct infection and malignant transformation less plausible. Below, the mechanisms, numbers, edge cases, and the practical takeaways for anyone weighing HPV vaccination against endometrial cancer risk.

Mechanism: Why the Uterine Lining Is a Poor Host for HPV

HPV needs dividing basal epithelial cells to establish infection. The virus enters through microabrasions, delivers its DNA to the nucleus, and depends on epithelial differentiation to complete its life cycle. The cervix provides exactly this niche at the squamocolumnar junction. The endometrium does not: it is a glandular lining with its own hormonal cycle, shedding monthly, and its stem-cell compartment sits beneath a protective layer.

HPV's cancer-causing proteins, E6 and E7, disable two tumor suppressors: p53 and retinoblastoma protein (Rb). This mechanism is powerful in cervical tissue but requires sustained infection of the right cell type. Endometrial cancers are driven by different lesions — PTEN loss, PIK3CA mutations, ARID1A loss, and mismatch repair defects in type I tumors; p53 mutations in type II serous tumors. The molecular fingerprints rarely overlap.

There is one anatomical nuance worth knowing. The lower uterine segment shares embryologic origins with the cervix, and HPV has occasionally been detected there in small studies. Even so, detection is not causation. Finding viral DNA in a tumor can reflect contamination, latent virus, or bystander presence. Koch-style criteria and modern causal frameworks require more: consistent association, dose-response, temporality, and biologic plausibility. None are established for HPV and endometrial cancer.

Quantified Context: How Often HPV Appears, and What Drives Endometrial Cancer Instead

Detection rates of HPV DNA in endometrial carcinoma are consistently low. Across studies and meta-analyses, HPV positivity in endometrial tumor tissue has generally been reported in the low single digits to roughly one in ten, with wide variation by geography, assay sensitivity, and tissue handling. Many well-controlled series report near zero. Compare that with cervical cancer, where HPV is detected in roughly 95 percent or more of tumors — a causal signature so strong it anchors global screening policy.

The real drivers of endometrial cancer are quantified and well replicated. Obesity, type 2 diabetes, hypertension, and chronic unopposed estrogen exposure account for a large share of type I endometrioid tumors. Endometrial cancer is the most common gynecologic malignancy in the United States, with an estimated tens of thousands of new cases annually and rising incidence tracking obesity rates. Most cases are diagnosed at an early stage because postmenopausal bleeding prompts evaluation.

HPV prevalence in the general population is high — often quoted around 40 percent of adults in their reproductive years for any genital HPV type, with most infections clearing within one to two years. If HPV caused endometrial cancer, the tumor would be vastly more common than it is. That mismatch is itself evidence against causation. The table below contrasts what is established for each HPV-linked cancer versus the endometrium.

Site HPV-attributable fraction (approx.) Dominant tissue type Causal status
Cervix ~95%+ Squamous/glandular transformation zone Established cause
Anus ~90% Squamous epithelium Established cause
Oropharynx ~70% Squamous epithelium Established cause
Vulva (subset) ~40% Squamous epithelium Established cause
Vagina ~65% Squamous epithelium Established cause
Endometrium Low single digits or less Glandular columnar lining Not established
Ovary Near zero Surface epithelium Not established

The rows for endometrium and ovary are qualitatively different in kind, not just degree. That is the core of the answer to whether HPV causes endometrial cancer: it does not, on current evidence.

Edge Cases: Where the Story Gets Complicated

Rare case reports describe HPV-positive endometrial tumors, and a few small series suggest higher detection in certain populations or in tumors near the lower uterine segment. These observations are interesting but cannot establish causation for several reasons. Detection methods vary enormously, contamination from the cervix or vagina during sampling is possible, and small sample sizes invite chance findings.

Another edge case is co-infection. A person with cervical HPV may also have endometrial pathology found incidentally. Simultaneous presence does not imply the virus caused the uterine tumor. Clinicians who see both findings in one patient should treat them as separate problems with separate workups.

Immunosuppression is a legitimate area of uncertainty. People with HIV or on chronic immunosuppression have higher rates of HPV persistence and HPV-related cancers. Whether their endometrial cancer risk shifts with HPV status is not established, and current guidance does not treat HPV as an endometrial risk factor in this group. That is a genuine gap, not a secret link.

There is also a diagnostic trap. Some endometrial tumors have squamous elements — adenosquamous or squamous differentiation. A pathologist may look for HPV in these areas expecting cervical-type biology. The squamous component of an endometrial tumor is not evidence of HPV causation; it reflects metaplasia or differentiation within the glandular tumor. Relying on morphology alone to impute HPV is a classic reasoning error.

Misconceptions: What People Get Wrong

The most common misconception is that because HPV causes one gynecologic cancer, it causes them all. Cancers are defined by their tissue of origin and their molecular drivers, not by their location in the reproductive tract. Cervical and endometrial cancers sit inches apart anatomically and are fundamentally different diseases in cause, risk factors, and treatment.

A second misconception confuses HPV testing with endometrial screening. HPV tests are validated for cervical sampling and are not designed or approved to screen for endometrial cancer. A positive HPV test says nothing about the uterine lining. Conversely, a negative HPV test does not rule out endometrial cancer — it is not a test for it at all.

A third error is reading correlation as causation from surveillance data. HPV vaccination programs reduce cervical, anal, and oropharyngeal disease, and some observational studies note broader trends. It would be a stretch to attribute endometrial cancer declines to vaccination without mechanistic support and randomized evidence. The honest position is that vaccination is expected to reduce HPV-attributable cancers, and endometrial cancer is not currently counted among them.

Warnings worth keeping in mind:

Postmenopausal bleeding is the key red flag for endometrial cancer and needs prompt evaluation regardless of HPV status. A positive HPV test should never be interpreted as explaining uterine symptoms. Do not skip endometrial evaluation because a patient was recently HPV-vaccinated or HPV-negative. Abnormal uterine bleeding on tamoxifen or unopposed estrogen warrants imaging and biopsy consideration, not an HPV test. Do not attribute an endometrial tumor with squamous features to HPV without molecular confirmation, and even then treat causation cautiously.

Timeline: What Happens When, and Why Timing Undermines Causation

Causal inference depends on temporality: exposure must precede disease by a plausible interval. HPV-associated cancers typically arise one to several decades after infection. Endometrial cancer has its own timeline tied to hormonal exposure and age. The table lays out the relevant windows qualitatively, since exact latencies vary by individual and cannot be pinned to a single number.

Event Typical timing Relevance to causality
HPV acquisition Usually within a few years of sexual debut Exposure is early and common
Cervical precancer Years to a decade after infection Demonstrates HPV latency
Cervical cancer Often 15-25 years after infection Long lag typical of HPV cancers
Endometrial hyperplasia Months to years of unopposed estrogen Hormonal, not viral, progression
Endometrial cancer diagnosis Usually ages 55-65, often postmenopausal Risk tracks obesity and estrogen
HPV vaccination Before sexual debut or catch-up Prevents HPV acquisition
Post-vaccine cancer decline Measured over decades Hard to attribute across cancer types

The timelines do not align in a way that supports HPV as an endometrial carcinogen. Endometrial cancer clusters around menopause and metabolic risk, while HPV exposure peaks decades earlier and produces cancers at epithelial transition zones. If HPV were a meaningful cause, the age and risk-factor patterns would look different.

Practical Actions: What to Do With This Information

For individuals, the actionable steps are straightforward and map to established guidance rather than speculative HPV-endometrial links. Vaccinate against HPV to prevent the cancers HPV does cause. Track and report abnormal uterine bleeding, especially after menopause. Manage metabolic risk factors that drive endometrial cancer. The numbered steps below convert this into a checklist, with thresholds stated explicitly and reconciled where guidance varies.

Get HPV vaccination per current immunization schedules. Catch-up vaccination is recommended through age 26 for most people, and shared clinical decision-making extends to age 45. The vaccine prevents HPV acquisition; it is not a treatment for existing infection and is not positioned as endometrial cancer prevention. Treat postmenopausal bleeding as a red flag. Any bleeding after menopause warrants evaluation, typically transvaginal ultrasound with endometrial thickness assessment and endometrial sampling. A common ultrasound threshold for further tissue sampling is an endometrial thickness of about 4 millimeters or more, though thresholds differ by guideline and clinical context; reconcile them with your clinician rather than applying one number universally. Address metabolic drivers. Weight management, glycemic control in diabetes, and blood pressure control reduce type I endometrial cancer risk. These are population-level levers with strong evidence, unlike HPV status. Review hormonal exposures. Unopposed estrogen, including some tamoxifen use, raises endometrial cancer risk. Discuss appropriate surveillance with a clinician; do not substitute HPV testing. Do not use HPV tests for uterine symptoms. There is no validated role for HPV testing in endometrial cancer screening or diagnosis.

A caveat on the numbers: endometrial thickness thresholds and vaccination age cutoffs are set by professional societies and public health bodies, and they are updated periodically. Confirm current guidance with a clinician or the relevant authority rather than relying on any single figure.

Limitations: What the Evidence Can and Cannot Say

Absence of evidence is not absolute proof of no effect, and intellectual honesty requires stating that boundary. HPV detection in endometrial tumors is low but not universally zero, and rare case reports exist. Very small studies cannot rule out a tiny contribution in a susceptible subgroup. What the evidence does support is a clear answer to the practical question: HPV is not an established cause of endometrial cancer, and treating it as one would misdirect screening and prevention.

Most available data are cross-sectional or retrospective, with heterogeneous detection methods and limited adjustment for confounders such as obesity and age. There is no randomized trial of HPV status and endometrial cancer outcomes, and there likely never will be, because such a trial would be impractical and unnecessary. Causal inference here rests on mechanistic biology, consistent epidemiologic patterns, and the divergent molecular profiles of the two diseases.

The forward-looking picture is stable. HPV vaccination is expected to reduce the cancers HPV causes, and endometrial cancer prevention will continue to center on metabolic health, hormonal risk management, and prompt evaluation of abnormal bleeding. No credible body currently lists HPV as an endometrial carcinogen. The best available synthesis: does HPV cause endometrial cancer? The evidence says no, and the reasons are mechanistic, quantitative, and consistent across the research literature.